Migraine Drugs Market - Global Industry Insights, Trends, Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Seattle, WA -- (SBWire) -- 11/14/2019 --Global Migraine Drugs Market – Insights

Migraine is a mental disorder that is characterized by severe pain in the head, nausea, vomiting, and extreme sensitivity to light and sound. Factors that influence migraine include, hormonal changes in female body, salty food and processed food, alcohol drinks, medications such as oral contraceptive and vasodilators such as nitroglycerin. There are two types of migraines: with aura (classical migraines) and without aura (common migraines). Aura is a symptom of nervous system and leads to visual disturbance such as flashes of light or zigzag vision and occurs before or during a migraine. Around 20 to 60 minutes of vision loss occurs in visual disturbance, along with pins, needles sensation in arms. It may also cause difficulty in speaking and uncontrollable movements of body. The symptoms of the disease are evident both during childhood and adulthood. The condition may progress through four stages: prodrome, aura, headache, and postdrome. The prevalence of migraine is more in women compared to men due to the hormonal influences. Drugs used in the treatment of migraine include, anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, sumatriptan, zolmitriptan, naproxen, and anti-sickness medicines.

Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/575

Global Migraine Drugs Market – Taxonomy

By Drugs Type:

- Painkillers
- Ergotamine
- Triptans
- Ant nausea drugs
- Opioids
- Beta-Blockers
- Calcium Channel Blocker
- Antidepressants

By Geography:

- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa

Global Migraine Drugs Market: Drivers

Excessive consumption of alcohol and oral contraceptives leads to high risk of migraine disorder. Increasing prevalence of migraine is a major factor boosting growth of the market. For instance, according to the World Health Organization (WHO) in 2016, half to three quarters of adults aged 18–65 years in the world have had headache in the last year and, among those individuals, 30% or more have reported migraine. According to the Migraine Research Foundation (MRF), migraine is a common neurological disease, around 38 million population including men, women and children in the U.S and 1 billion population around the globe is affected by it as of 2017. Increasing awareness about migraine treatment drugs is also influencing the market growth.

Request For Customization at: https://www.coherentmarketinsights.com/insight/request-customization/575

Increasing technological developments such as smartphone controlled wireless patch that uses electrical stimulation to reduce the pain of migraines is expected to boost growth of the global migraine drugs market. Moreover, increasing R&D of new margarine drugs is also expected to boost growth of the market. For instance, in June 2017, Cadila Healthcare Ltd. (Zydus Cadila) received approval to market Eletriptan Hydrobromide tablets (20 mg and 40 mg) that are used for the treatment of migraine from the Food and Drug Administration (FDA). In June 2017, Novartis applied for marketing authorization of its drug erenumab for the treatment of migraine to the European Medicines Agency (EMA). Moreover, Israel-based multinational pharmaceutical company, Teva Pharmaceuticals Industries Ltd. is expected to file approval for fremanezumab (TEV-48125) drug for the treatment of chronic migraine and the episodic migraine to the Food and Drug Administration (FDA) in 2017 and the drug is expected to be commercialized by the second half of 2018.

Global Migraine Drugs Market: Regional Analysis

On the basis of region, the global migraine drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global migraine drugs market, owing to increasing geriatric population. For instance, according to the U.S. Census Bureau in 2013, geriatric population was around 14.1%. Moreover, according to the National Headache Foundation (NHF), the U.S. spends over US$ 4 billion, annually on drugs for the treatment of migraine.

Global Migraine Drugs Market: Competitive Landscape

Major players operating in the global migraine drugs market include, Amgen Inc., Endo International plc., Pfizer Inc., Alder BioPharmaceuticals Inc.,Astellas Pharma Inc., Aegis Therapeutics, LLC., Aeriel BioPharma, CoLucid Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., IntelGenx Corp., Johnson & Johnson, Kowa Pharmaceuticals America, Valeant Pharmaceuticals International, Inc., Luitpold Pharmaceuticals, Teva Pharmaceutical Industries LTD.,WINSTON PHARMACEUTICALS, Inc., Zogenix Inc., Abbott Laboratories, AstraZeneca plc., and GlaxoSmithKline plc.

Global Migraine Drugs Market: Taxonomy:

By Drug Type:
- Ergotamine
- Triptans
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Others
By Route of Administration:
- Oral
- Parenteral
By Distribution Channel:
- Hospital Pharmacies  
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe  
- Asia Pacific
- Middle East
- Africa

For More Details On this Report: https://www.coherentmarketinsights.com/ongoing-insight/migraine-drugs-market-575